Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Neoadjuvant Chemotherapy Plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage Ovarian Cancer (TRU-D)

NCT03899610 is registered in ClinicalTrials.gov with Yonsei University as lead sponsor.

NCT NCT03899610
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03899610 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Neoadjuvant Chemotherapy Plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage Ovarian Cancer (TRU-D)
Lead sponsor
Yonsei University
Phase
Phase 2
Overall status
Unknown status
Start date
July 4, 2019
Completion date
May 31, 2021
Enrollment
24 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer stage iiic, ovarian cancer stage iv